Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Jun 29. pii: S0360-3016(18)31014-9. doi: 10.1016/j.ijrobp.2018.06.023. [Epub ahead of print]

PMID:
29966725
2.

Intake of dietary carbohydrates in early adulthood and adolescence and breast density among young women.

Jung S, Goloubeva O, Hylton N, Klifa C, LeBlanc E, Shepherd J, Snetselaar L, Van Horn L, Dorgan JF.

Cancer Causes Control. 2018 Jul;29(7):631-642. doi: 10.1007/s10552-018-1040-1. Epub 2018 May 25.

PMID:
29802491
3.

MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.

Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM; ACRIN 6657 Trial Team and I-SPY Investigators Network.

AJR Am J Roentgenol. 2018 Jun;210(6):1376-1385. doi: 10.2214/AJR.17.18323. Epub 2018 Apr 30.

PMID:
29708782
4.

Assessing the Nature of the Distribution of Localised States in Bulk GaAsBi.

Wilson T, Hylton NP, Harada Y, Pearce P, Alonso-Álvarez D, Mellor A, Richards RD, David JPR, Ekins-Daukes NJ.

Sci Rep. 2018 Apr 24;8(1):6457. doi: 10.1038/s41598-018-24696-2.

5.

Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial

Leproux A, O'Sullivan TD, Cerussi A, Durkin A, Hill B, Hylton N, Yodh AG, Carp SA, Boas D, Jiang S, Paulsen KD, Pogue B, Roblyer D, Yang W, Tromberg BJ.

J Biomed Opt. 2017 Dec 1;22(12):121604. Epub 2017 Aug 17.

PMID:
29389104
6.

Features of MRI stromal enhancement with neoadjuvant chemotherapy: a subgroup analysis of the ACRIN 6657/I-SPY TRIAL.

Olshen A, Wolf D, Jones EF, Newitt D, van ‘t Veer LJ, Yau C, Esserman L, Wulfkuhle JD, Gallagher RI, Singer L, Petricoin EF 3rd, Hylton N, Park CC.

J Med Imaging (Bellingham). 2018 Jan;5(1):011014. doi: 10.1117/1.JMI.5.1.011014. Epub 2017 Dec 23.

PMID:
29296631
7.

Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices.

Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN.

Radiology. 2018 Mar;286(3):822-829. doi: 10.1148/radiol.2017170811. Epub 2017 Oct 25.

PMID:
29072981
8.

Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network.

Newitt DC, Malyarenko D, Chenevert TL, Quarles CC, Bell L, Fedorov A, Fennessy F, Jacobs MA, Solaiyappan M, Hectors S, Taouli B, Muzi M, Kinahan PE, Schmainda KM, Prah MA, Taber EN, Kroenke C, Huang W, Arlinghaus LR, Yankeelov TE, Cao Y, Aryal M, Yen YF, Kalpathy-Cramer J, Shukla-Dave A, Fung M, Liang J, Boss M, Hylton N.

J Med Imaging (Bellingham). 2018 Jan;5(1):011003. doi: 10.1117/1.JMI.5.1.011003. Epub 2017 Oct 10.

PMID:
29021993
9.

DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L.

NPJ Breast Cancer. 2017 Aug 25;3:31. doi: 10.1038/s41523-017-0025-7. eCollection 2017.

10.

Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study.

Bane O, Hectors SJ, Wagner M, Arlinghaus LL, Aryal MP, Cao Y, Chenevert TL, Fennessy F, Huang W, Hylton NM, Kalpathy-Cramer J, Keenan KE, Malyarenko DI, Mulkern RV, Newitt DC, Russek SE, Stupic KF, Tudorica A, Wilmes LJ, Yankeelov TE, Yen YF, Boss MA, Taouli B.

Magn Reson Med. 2018 May;79(5):2564-2575. doi: 10.1002/mrm.26903. Epub 2017 Sep 14.

PMID:
28913930
11.

Computational Challenges and Collaborative Projects in the NCI Quantitative Imaging Network.

Farahani K, Kalpathy-Cramer J, Chenevert TL, Rubin DL, Sunderland JJ, Nordstrom RJ, Buatti J, Hylton N.

Tomography. 2016 Dec;2(4):242-249. doi: 10.18383/j.tom.2016.00265.

12.

Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.

Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM.

Clin Breast Cancer. 2017 Jun;17(3):e155-e159. doi: 10.1016/j.clbc.2016.12.008. Epub 2016 Dec 29. No abstract available.

PMID:
28110902
13.

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.

Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM; ACRIN 6657 Trial Team and I-SPY Investigators Network.

Tomography. 2016 Dec;2(4):378-387. doi: 10.18383/j.tom.2016.00247.

14.

MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.

Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM; ACRIN Trial team ISPY-1 Investigators.

J Magn Reson Imaging. 2017 Jul;46(1):290-302. doi: 10.1002/jmri.25560. Epub 2016 Dec 16.

15.

Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.

Wilmes LJ, Li W, Shin HJ, Newitt DC, Proctor E, Harnish R, Hylton NM.

Tomography. 2016 Dec;2(4):438-447. doi: 10.18383/j.tom.2016.00271.

16.

Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging.

Tromberg BJ, Zhang Z, Leproux A, O'Sullivan TD, Cerussi AE, Carpenter PM, Mehta RS, Roblyer D, Yang W, Paulsen KD, Pogue BW, Jiang S, Kaufman PA, Yodh AG, Chung SH, Schnall M, Snyder BS, Hylton N, Boas DA, Carp SA, Isakoff SJ, Mankoff D; ACRIN 6691 investigators.

Cancer Res. 2016 Oct 15;76(20):5933-5944. Epub 2016 Aug 15.

17.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

18.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

19.

Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women.

Bertrand KA, Baer HJ, Orav EJ, Klifa C, Kumar A, Hylton NM, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1151-7. doi: 10.1158/1055-9965.EPI-16-0185. Epub 2016 May 9.

20.

Variability and bias assessment in breast ADC measurement across multiple systems.

Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton NM.

J Magn Reson Imaging. 2016 Oct;44(4):846-55. doi: 10.1002/jmri.25237. Epub 2016 Mar 23.

21.

Design of a breast phantom for quantitative MRI.

Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton NM.

J Magn Reson Imaging. 2016 Sep;44(3):610-9. doi: 10.1002/jmri.25214. Epub 2016 Mar 7.

22.

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.

Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM.

PLoS One. 2016 Feb 17;11(2):e0142047. doi: 10.1371/journal.pone.0142047. eCollection 2016.

23.

Quantitative Imaging in Cancer Clinical Trials.

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.

Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. Review.

24.

Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.

Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators.

Radiology. 2016 Apr;279(1):44-55. doi: 10.1148/radiol.2015150013. Epub 2015 Dec 1.

25.

How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.

Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ.

World J Clin Cases. 2015 Jul 16;3(7):607-13. doi: 10.12998/wjcc.v3.i7.607. Review.

26.

Body fatness during childhood and adolescence and breast density in young women: a prospective analysis.

Bertrand KA, Baer HJ, Orav EJ, Klifa C, Shepherd JA, Van Horn L, Snetselaar L, Stevens VJ, Hylton NM, Dorgan JF.

Breast Cancer Res. 2015 Jul 16;17:95. doi: 10.1186/s13058-015-0601-4.

27.

Adolescent endogenous sex hormones and breast density in early adulthood.

Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF.

Breast Cancer Res. 2015 Jun 4;17:77. doi: 10.1186/s13058-015-0581-4.

28.

Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.

Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD.

PLoS One. 2015 Mar 27;10(3):e0122151. doi: 10.1371/journal.pone.0122151. eCollection 2015.

29.

Extra-mammary findings on breast MRI: a pictorial review.

Karp NL, Price ER, Wisner DJ, Chang CB, Hylton NM, Joe BN.

Clin Imaging. 2015 Jul-Aug;39(4):547-52. doi: 10.1016/j.clinimag.2015.01.019. Epub 2015 Feb 24. Review.

PMID:
25772531
30.

Gradient nonlinearity correction to improve apparent diffusion coefficient accuracy and standardization in the american college of radiology imaging network 6698 breast cancer trial.

Newitt DC, Tan ET, Wilmes LJ, Chenevert TL, Kornak J, Marinelli L, Hylton N.

J Magn Reson Imaging. 2015 Oct;42(4):908-19. doi: 10.1002/jmri.24883. Epub 2015 Mar 11.

31.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

32.

Lesion morphology on breast MRI affects targeted ultrasound correlation rate.

Hollowell L, Price E, Arasu V, Wisner D, Hylton N, Joe B.

Eur Radiol. 2015 May;25(5):1279-84. doi: 10.1007/s00330-014-3517-y. Epub 2014 Dec 12.

PMID:
25500714
33.

Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis.

Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1464-83. doi: 10.1158/1055-9965.EPI-13-1170. Epub 2014 May 7. Review.

34.

Repeatability of quantitative MRI measurements in normal breast tissue.

Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM.

Transl Oncol. 2014 Feb 1;7(1):130-7. eCollection 2014 Feb.

35.

Image registration for quantitative parametric response mapping of cancer treatment response.

Boes JL, Hoff BA, Hylton N, Pickles MD, Turnbull LW, Schott AF, Rehemtulla A, Chamberlain R, Lemasson B, Chenevert TL, Galbán CJ, Meyer CR, Ross BD.

Transl Oncol. 2014 Feb 1;7(1):101-10. eCollection 2014 Feb.

36.

Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.

Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM.

Transl Oncol. 2014 Feb 1;7(1):94-100. eCollection 2014 Feb.

37.

Errors in Quantitative Image Analysis due to Platform-Dependent Image Scaling.

Chenevert TL, Malyarenko DI, Newitt D, Li X, Jayatilake M, Tudorica A, Fedorov A, Kikinis R, Liu TT, Muzi M, Oborski MJ, Laymon CM, Li X, Thomas Y, Jayashree KC, Mountz JM, Kinahan PE, Rubin DL, Fennessy F, Huang W, Hylton N, Ross BD.

Transl Oncol. 2014 Feb 1;7(1):65-71. eCollection 2014 Feb.

38.

High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging.

McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM.

J Magn Reson Imaging. 2014 May;39(5):1308-13. doi: 10.1002/jmri.24283. Epub 2013 Oct 8.

39.

Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.

Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM.

J Magn Reson Imaging. 2014 Aug;40(2):476-82. doi: 10.1002/jmri.24351. Epub 2013 Dec 18.

40.

Agreement of mammographic measures of volumetric breast density to MRI.

Wang J, Azziz A, Fan B, Malkov S, Klifa C, Newitt D, Yitta S, Hylton N, Kerlikowske K, Shepherd JA.

PLoS One. 2013 Dec 4;8(12):e81653. doi: 10.1371/journal.pone.0081653. eCollection 2013.

41.

High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T.

Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM.

J Magn Reson Imaging. 2014 Sep;40(3):674-81. doi: 10.1002/jmri.24416. Epub 2013 Nov 8.

42.

Features of occult invasion in biopsy-proven DCIS at breast MRI.

Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM.

Breast J. 2013 Nov-Dec;19(6):650-8. doi: 10.1111/tbj.12201.

43.

Loss mitigation in plasmonic solar cells: aluminium nanoparticles for broadband photocurrent enhancements in GaAs photodiodes.

Hylton NP, Li XF, Giannini V, Lee KH, Ekins-Daukes NJ, Loo J, Vercruysse D, Van Dorpe P, Sodabanlu H, Sugiyama M, Maier SA.

Sci Rep. 2013 Oct 7;3:2874. doi: 10.1038/srep02874.

44.

Menstrual and reproductive characteristics and breast density in young women.

Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO Jr, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM.

Cancer Causes Control. 2013 Nov;24(11):1973-83. doi: 10.1007/s10552-013-0273-2. Epub 2013 Aug 10.

45.

Breast magnetic resonance imaging for monitoring response to therapy.

Ojeda-Fournier H, de Guzman J, Hylton N.

Magn Reson Imaging Clin N Am. 2013 Aug;21(3):533-46. doi: 10.1016/j.mric.2013.04.005. Review.

PMID:
23928243
46.

Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.

Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM.

Radiology. 2013 Nov;269(2):354-61. doi: 10.1148/radiol.13130058. Epub 2013 Jul 22.

47.

Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Mukhtar RA, Yau C, Rosen M, Tandon VJ; I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ.

Ann Surg Oncol. 2013 Nov;20(12):3823-30. doi: 10.1245/s10434-013-3038-y. Epub 2013 Jun 19.

48.

Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers.

Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD.

AJR Am J Roentgenol. 2013 Jun;200(6):W683-9. doi: 10.2214/AJR.11.8394.

49.

Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T.

Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM.

AJR Am J Roentgenol. 2013 Jun;200(6):W673-82. doi: 10.2214/AJR.12.10013. Review.

PMID:
23701101
50.

MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy.

Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM.

PLoS One. 2013 May 7;8(5):e61969. doi: 10.1371/journal.pone.0061969. Print 2013.

Supplemental Content

Loading ...
Support Center